A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer

Documenti analoghi

• Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
  di: Vallis, K, et al.
  Pubblicazione: (2014)
• A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
  di: Vallis, K, et al.
  Pubblicazione: (2005)
• Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
  di: Reilly, R, et al.
  Pubblicazione: (2006)
• Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
  di: Hu, M, et al.
  Pubblicazione: (2007)
• Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
  di: Wang, J, et al.
  Pubblicazione: (2001)